Cargando…

Possible association between diabetic ketoacidosis and use of sodium-glucose co-transporter 2 inhibitor in a 17-year-old youth with type 2 diabetes

Detalles Bibliográficos
Autores principales:	Shamchuk, Angela, Doulla, Manpreet, Jetha, Mary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	CMA Joule Inc. 2021
Materias:	Practice
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443299/ https://www.ncbi.nlm.nih.gov/pubmed/34493565 http://dx.doi.org/10.1503/cmaj.202627

Ejemplares similares

Association possible entre l’acidocétose diabétique et l’utilisation d’un inhibiteur du sodium-glucose co-transporteur 2 chez un jeune de 17 ans atteint de diabète de type 2
por: Shamchuk, Angela, et al.
Publicado: (2021)

Sodium-Glucose Transport Protein 2 Inhibitors Association with Euglycemic Diabetic Ketoacidosis
por: Wojtas, Caroline, et al.
Publicado: (2023)

Sodium Glucose Transporter 2 Inhibitors and Diabetic Ketoacidosis in Three Patients with Diabetes: Underlying Causation
por: Kelley, Jordan L., et al.
Publicado: (2017)

Sodium–glucose cotransporter-2 inhibitors in patients without diabetes
por: Fryml, Elise, et al.
Publicado: (2023)

Sodium-glucose Cotransporter-2 Induced Diabetic Ketoacidosis with Minimal Hyperglycemia
por: Gammons, D. Taylor, et al.
Publicado: (2018)

Prurigo pigmentosa with new-onset diabetic ketoacidosis
por: Coulombe, Jérôme, et al.
Publicado: (2021)

Euglycemic diabetic ketoacidosis by sodium glucose co-transporter inhibitors: Real but preventable concern
por: Raut, Monish S, et al.
Publicado: (2017)

Sodium-glucose co-transporter 2 inhibitors induced euglycemic diabetic ketoacidosis within four days of initiation
por: Razok, Almurtada, et al.
Publicado: (2022)

Euglycemic diabetic ketoacidosis in a patient with acute stroke taking sodium glucose co-transporter 2 inhibitor
por: Pathak, Bishnu Deep, et al.
Publicado: (2022)

Two Cases of Thyrotoxicosis and Euglycemic Diabetic Ketoacidosis Under Sodium-glucose Transport Protein 2 Inhibitor Treatment
por: Hitsuwari, Takuhei, et al.
Publicado: (2022)

Euglycemic diabetic ketoacidosis: A rare but serious side effect of sodium-glucose co-transporter 2 inhibitors
por: Lakušić, Nenad, et al.
Publicado: (2022)

Fournier’s Gangrene and Diabetic Ketoacidosis Associated with Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Life-Threatening Complications
por: Kasbawala, Kinjal, et al.
Publicado: (2020)

Severe euglycemic diabetic ketoacidosis secondary to sodium-glucose co-transporter 2 inhibitor: case report and literature review
por: El Ess, Malak S., et al.
Publicado: (2023)

Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight
por: Singh, Awadhesh Kumar
Publicado: (2015)

Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin
por: Kelmenson, Daniel A., et al.
Publicado: (2017)

Sodium-Glucose Linked Transporter Inhibitors as a Cause of Euglycemic Diabetic Ketoacidosis on a Background of Starvation
por: Tauseef, Abubakar, et al.
Publicado: (2020)

OR31-1 Sodium-Glucose Co-Transporter-2 Inhibitors and the Risk of Diabetic Ketoacidosis: Clinical and Biochemical Characteristics of 21 Cases
por: Stamatiades, George, et al.
Publicado: (2019)

Patient-Specific Risk Factors and Clinical Correlates of Euglycemic Diabetic Ketoacidosis in Patients on Sodium-Glucose Co-Transporter-2 Inhibitors
por: Somagutta, Manoj Reddy, et al.
Publicado: (2021)

SUN-673 Development of Euglycemic Diabetic Ketoacidosis in a Patient with Well-Controlled Type 2 Diabetes Mellitus on a Sodium-Glucose Transporter 2 Inhibitor
por: Narang, Disha K, et al.
Publicado: (2020)

Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis
por: Stougaard, Elisabeth B, et al.
Publicado: (2022)

Sodium-glucose Cotransporter 2 Inhibitors and Ketoacidosis – Clinical Implications in the Treatment of Patients with Type 2 Diabetes
por: Stinkens, Kirsten, et al.
Publicado: (2016)

Sodium-glucose co-transporter-2 inhibitor-associated euglycemic diabetic ketoacidosis that prompted the diagnosis of fulminant type-1 diabetes: A case report
por: Yasuma, Taro, et al.
Publicado: (2021)

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition
por: Peters, Anne L., et al.
Publicado: (2015)

Sodium–Glucose Cotransporter 2 Inhibitors and Euglycemic Diabetic Ketoacidosis: Metabolic Acidosis With a Twist
por: Jaberi, Aala, et al.
Publicado: (2016)

Sodium-glucose Cotransporter-2 Inhibitors and Euglycaemic Diabetic Ketoacidosis in the Perioperative Period: Case Report
por: Jhaveri, Urmita, et al.
Publicado: (2019)

Sodium-Glucose Cotransporter-2 Inhibitor-Related Diabetic Ketoacidosis: Accuracy Verification of Operational Definition
por: Kang, Dong Yoon, et al.
Publicado: (2022)

Concurrent diabetic ketoacidosis with hyperosmolality and/or severe hyperglycemia in youth with type 2 diabetes
por: Schmitt, Jessica, et al.
Publicado: (2020)

Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin
por: Bader, Nimrah, et al.
Publicado: (2016)

Euglycemic Diabetic Ketoacidosis in Concurrent Very Low-carbohydrate Diet and Sodium-glucose Transporter-2 Inhibitor Use: A Case Report
por: Earle, Matthew, et al.
Publicado: (2020)

Sodium-Glucose Co-transporter 2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis After Bariatric Surgery: A Case and Literature Review
por: Kapila, Vaishali, et al.
Publicado: (2021)

Diabetic Ketoacidosis-Associated Stroke in Children and Youth
por: Foster, Jennifer Ruth, et al.
Publicado: (2011)

A Review of the Efficacy and Safety of Sodium–Glucose Cotransporter 2 Inhibitors: A Focus on Diabetic Ketoacidosis
por: Zurek, Ashley M., et al.
Publicado: (2017)

Periprocedural Euglycemic Diabetic Ketoacidosis Associated With Sodium–Glucose Cotransporter 2 Inhibitor Therapy During Colonoscopy
por: Meyer, Emily J., et al.
Publicado: (2020)

Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter 2 Inhibitors: Clinical and Biochemical Characteristics of 29 Cases
por: Stamatiades, G. A., et al.
Publicado: (2023)

MON-652 The Prevalence and Clinical Characteristics of Adult Patients Presenting with Sodium-Glucose Co-Transporter-2 Inhibitor Associated Euglycemic Diabetic Ketoacidosis
por: Clark, Alexa, et al.
Publicado: (2020)

Sodium–glucose cotransporter 2 inhibitor‐associated diabetic ketoacidosis in patients with type 1 diabetes: Metabolic imbalance as an underlying mechanism
por: Ogawa, Wataru, et al.
Publicado: (2019)

On‐label use of sodium–glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes
por: Horii, Takeshi, et al.
Publicado: (2021)

Sodium-glucose co-transporter 2 inhibitors beyond diabetes
por: Williams, Dimity L, et al.
Publicado: (2022)

Euglycemic Diabetic Ketoacidosis Due to Sodium–Glucose Cotransporter 2 Inhibitor Use in Two Patients Undergoing Pancreatectomy
por: Pace, Devon J., et al.
Publicado: (2018)

Sodium–Glucose Cotransporter 2 Inhibitors and Diabetic Ketoacidosis: A Case Series From Three Academic Institutions
por: Misaghian-Xanthos, Negin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_o2ummo90t1sj89sp31a2pu2321